Literature DB >> 26760234

Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients.

María A Jiménez-Sousa1, Juan Berenguer, Mónica García-Álvarez, Mónica Gutierrez-Rivas, Teresa Aldámiz-Echevarria, Francisco Tejerina, Cristina Diez, Sonia Vázquez-Morón, Salvador Resino.   

Abstract

OBJECTIVE: To analyze the association between patatin-like phospholipase domain-containing 3 gene (PNPLA3) rs738409 polymorphism and severity of liver disease in HIV/hepatitis C virus-coinfected patients.
METHODS: We performed a cross-sectional study of 215 patients who underwent a liver biopsy. PNPLA3 rs738409 polymorphism was genotyped using GoldenGate assay. The outcome variables were as follows: advanced fibrosis (F ≥3 and FIB-4 ≥3.25), rapid fibrosis progression (FPR ≥0.10 fibrosis units/year), severe activity grade (A≥3), and steatosis (fatty hepatocytes ≥10%). The genetic association analysis was carried out according to an additive genetic model through logistic regressions adjusted by the most significant covariables.
RESULTS: Overall, 21.4% had F at least 3, 8.9% had FIB-4 at least 3.25, 11.4% had A at least 3, 60.6% had steatosis, and 32.5% had FPR at least 0.10. For each rs738409 G allele, we found an increased frequency of patients with advanced fibrosis (F at least 3) (0% CC, 18.5% CG, and 25.2% GG; P = 0.049) and FIB-4 at least 3.25 (0% CC, 3.8% CG, and 13.2% GG; P = 0.016). Furthermore, for each rs738409 G allele, the odds of having F at least 3 increased 2.15 times (95% confidence interval=1.07; 4.35; P = 0.029) and having FIB-4 at least 3.25 increased 8.77 times (95% of confidence interval = 1.11; 69.0; P = 0.039). Note that rs738409 G allele carriers tended to higher likelihood of having FPR at least 0.10, but statistical significance was not reached (P = 0.054). Finally, we did not find any association for A at least 3 and liver steatosis.
CONCLUSION: PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26760234     DOI: 10.1097/QAD.0000000000000908

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals.

Authors:  Kenneth E Sherman; Susan D Rouster; Minhee Kang; Triin Umbleja; Richard Sterling; Adeel A Butt
Journal:  Dig Dis Sci       Date:  2018-09-14       Impact factor: 3.199

Review 2.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.

Authors:  Jürgen Kurt Rockstroh
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

Review 3.  NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Authors:  Subada Soti; Kathleen E Corey; Jordan E Lake; Kristine M Erlandson
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

4.  The Ethics of Precision Rationing: Human Genetics and the Need for Debate on Stratifying Access to Medication.

Authors:  Alexis Walker; Angie Boyce; Priya Duggal; Chloe L Thio; Gail Geller
Journal:  Public Health Genomics       Date:  2020-06-09       Impact factor: 2.000

5.  The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.

Authors:  Rocío Núñez-Torres; Juan Macías; María Mancebo; Mario Frías; Giovanni Dolci; Francisco Téllez; Dolores Merino; Nicolás Merchante; Jesús Gómez-Mateos; Giovanni Guaraldi; Antonio Rivero-Juárez; Juan A Pineda; Luis M Real
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

6.  Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study.

Authors:  Mónica García-Álvarez; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Francisco Tejerina; Cristina Diez; Sonia Vázquez-Morón; Salvador Resino
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

7.  Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART).

Authors:  Leona Dold; Carolin Luda; Carolynne Schwarze-Zander; Christoph Boesecke; Cordula Hansel; Hans-Dieter Nischalke; Philipp Lutz; Raphael Mohr; Jan-Christian Wasmuth; Christian P Strassburg; Jonel Trebicka; Jürgen Kurt Rockstroh; Ulrich Spengler
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

8.  The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection

Authors:  Rattanaporn Kiatbumrung; Natthaya Chuaypen; Sunchai Payungporn; Anchalee Avihingsanon; Pisit Tangkijvanich
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24

Review 9.  PNPLA3 expression and its impact on the liver: current perspectives.

Authors:  Francesca Virginia Bruschi; Matteo Tardelli; Thierry Claudel; Michael Trauner
Journal:  Hepat Med       Date:  2017-11-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.